These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 2144819

  • 1. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
    Di Silverio F, Sciarra F, D'Eramo G.
    Eur Urol; 1990; 18(1):10-5. PubMed ID: 2144819
    [Abstract] [Full Text] [Related]

  • 2. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H, Senge T.
    J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
    [Abstract] [Full Text] [Related]

  • 3. Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
    Bouffioux C.
    Eur Urol; 1988 Oct; 15(3-4):187-92. PubMed ID: 2975222
    [Abstract] [Full Text] [Related]

  • 4. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H, Varenhorst E, Svensson M, Kågedal B, Nordenskjöld B.
    Acta Oncol; 1988 Oct; 27(4):361-4. PubMed ID: 2974290
    [Abstract] [Full Text] [Related]

  • 5. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
    Waxman J.
    Prog Clin Biol Res; 1989 Oct; 303():61-8. PubMed ID: 2528741
    [No Abstract] [Full Text] [Related]

  • 6. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW, Uitterlinden P, de Jong FH.
    Cancer Res; 1988 Nov 01; 48(21):6063-8. PubMed ID: 2844399
    [Abstract] [Full Text] [Related]

  • 7. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
    Di Silverio F, Serio M, D'Eramo G, Sciarra F.
    Eur Urol; 1990 Nov 01; 18 Suppl 3():54-61. PubMed ID: 2151278
    [Abstract] [Full Text] [Related]

  • 8. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
    Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ.
    Cancer; 1996 Nov 15; 78(10):2164-9. PubMed ID: 8918410
    [Abstract] [Full Text] [Related]

  • 9. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
    Moffat LE.
    Eur Urol; 1990 Nov 15; 18 Suppl 3():26-7. PubMed ID: 2151272
    [No Abstract] [Full Text] [Related]

  • 10. [Lack of effect of therapy with LHRH analogs, alone or associated with flutamide, on prolactin levels in advanced prostatic carcinoma].
    Banchini A, Zavaroni D, Tarditi E, Cortellini P, Ziveri M, Polotti R, Stefani F, Valenti G.
    Minerva Endocrinol; 1989 Nov 15; 14(3):165-8. PubMed ID: 2533662
    [Abstract] [Full Text] [Related]

  • 11. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
    Sugiono M, Winkler MH, Okeke AA, Benney M, Gillatt DA.
    Prostate Cancer Prostatic Dis; 2005 Nov 15; 8(1):91-4. PubMed ID: 15711607
    [Abstract] [Full Text] [Related]

  • 12. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
    Boccon-Gibod L, Laudat MH, Dugue MA, Steg A.
    Eur Urol; 1986 Nov 15; 12(6):400-2. PubMed ID: 2949980
    [Abstract] [Full Text] [Related]

  • 13. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Belanger A, Lacourciere Y, Emond J, Monfette G.
    J Steroid Biochem; 1986 Nov 15; 25(5B):877-83. PubMed ID: 3100871
    [Abstract] [Full Text] [Related]

  • 14. Effects of two different medical treatments on dihydrotestosterone content and androgen receptors in human benign prostatic hyperplasia.
    Petrangeli E, Sciarra F, Di Silverio F, Toscano V, Lubrano C, Conti C, Concolino G.
    J Steroid Biochem; 1988 Nov 15; 30(1-6):395-9. PubMed ID: 2455099
    [Abstract] [Full Text] [Related]

  • 15. Antiandrogens: clinical applications.
    Sciarra F, Toscano V, Concolino G, Di Silverio F.
    J Steroid Biochem Mol Biol; 1990 Nov 20; 37(3):349-62. PubMed ID: 2147859
    [Abstract] [Full Text] [Related]

  • 16. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
    Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M, Collette L, Members of the EORTC Genito-Urinary Group.
    Eur Urol; 2004 Apr 20; 45(4):457-64. PubMed ID: 15041109
    [Abstract] [Full Text] [Related]

  • 17. [A 79-year-old man with metastatic prostate cancer, treated with Zoladex, flutamide, calcitonin and Ostac, suffers from frequent troublesome sweating with palpitation and angina pectoris, especially at night. Is there a therapy?].
    Schmeller N.
    Internist (Berl); 1992 Apr 20; 33(4):284. PubMed ID: 1535344
    [No Abstract] [Full Text] [Related]

  • 18. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
    Allen JM, Williams G, O'Shea JP, Smith C, Yeo T, Kerle D, Bloom SR.
    Urol Res; 1984 Apr 20; 12(5):249-51. PubMed ID: 6240150
    [Abstract] [Full Text] [Related]

  • 19. Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma.
    Sogani PC, Whitmore WF.
    Cancer Treat Res; 1988 Apr 20; 39():131-45. PubMed ID: 2908604
    [Abstract] [Full Text] [Related]

  • 20. Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate.
    Paisey RB, Kadow C, Bolton C, Hartog M, Gingell JC.
    J R Soc Med; 1986 Apr 20; 79(4):210-1. PubMed ID: 2939240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.